Industry Strength Score
11/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
TALIS BIOMEDICAL CORP (TLIS) Stock Price & Overview
NASDAQ:TLIS • US87424L2079
Current stock price
4.38 USD
+0.22 (+5.29%)
At close:
4.49 USD
+0.11 (+2.51%)
After Hours:
The current stock price of TLIS is 4.38 USD. Today TLIS is up by 5.29%. In the past month the price decreased by -50.79%. In the past year, price decreased by -27.24%.
TLIS Key Statistics
52-Week Range3.42 - 9.6
Current TLIS stock price positioned within its 52-week range.
1-Month Range3.42 - 9.35
Current TLIS stock price positioned within its 1-month range.
- Market Cap
- 7.972M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -31.43
- Dividend Yield
- N/A
TLIS Stock Performance
Today
+5.29%
1 Week
-3.07%
1 Month
-50.79%
3 Months
-52.39%
Longer-term
6 Months -46.30%
1 Year -27.24%
2 Years -67.56%
3 Years -96.38%
5 Years N/A
10 Years N/A
TLIS Stock Chart
TLIS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TLIS. When comparing the yearly performance of all stocks, TLIS is a bad performer in the overall market: 91.67% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
TLIS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TLIS. While TLIS has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TLIS Earnings
Next Earnings DateNov 12, 2024
Last Earnings DateAug 7, 2024
PeriodQ2 / 2024
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
TLIS Forecast & Estimates
6 analysts have analysed TLIS and the average price target is 5.1 USD. This implies a price increase of 16.44% is expected in the next year compared to the current price of 4.38.
For the next year, analysts expect an EPS growth of 27.62% and a revenue growth -100% for TLIS
Analysts
Analysts36.67
Price Target5.1 (16.44%)
EPS Next Y27.62%
Revenue Next Year-100%
TLIS Financial Highlights
Over the last trailing twelve months TLIS reported a non-GAAP Earnings per Share(EPS) of -31.43. The EPS increased by 42.72% compared to the year before.
Income Statements
Revenue(TTM)989.00K
Net Income(TTM)-57.21M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.35% | ||
| ROE | -100.93% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%28.28%
Sales Q2Q%-93.25%
EPS 1Y (TTM)42.72%
Revenue 1Y (TTM)-65.21%
TLIS Ownership
Ownership
Inst Owners21.86%
Shares1.82M
Float1.67M
Ins Owners18.29%
Short Float %N/A
Short RatioN/A
TLIS Industry Overview
TLIS operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 127 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
60/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
22%
Outperformed 22% of sub-industries
3 Month Rank
14%
Outperformed 14% of sub-industries
6 Month Rank
11%
Outperformed 11% of sub-industries
Industry Fundamentals & Breadth
- Members
- 127
- New Highs
- 2.4%
- New Lows
- 14.2%
- Average ROE
- 17.2%
- Average Profit Margin
- 20.3%
- Average Operating Margin
- 22.5%
- Average P/E
- 28.3
- Average Fwd P/E
- 27.4
- Average Debt/Equity
- 0.5
TLIS Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 39.25 | 162.59B | ||
| ABT | ABBOTT LABORATORIES | 14.24 | 155.452B | ||
| SYK | STRYKER CORP | 17.41 | 112.876B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.31 | 83.969B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.9 | 48.418B | ||
| IDXX | IDEXX LABORATORIES INC | 38.32 | 45.068B | ||
| BDX | BECTON DICKINSON AND CO | 10.94 | 42.515B | ||
| RMD | RESMED INC | 16.7 | 29.867B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 10.74 | 27.847B | ||
| DXCM | DEXCOM INC | 20.18 | 23.611B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.11 | 16.047B | ||
| PEN | PENUMBRA INC | 63.83 | 12.792B | ||
| GMED | GLOBUS MEDICAL INC - A | 20.03 | 12.354B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TLIS
Company Profile
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Chicago, Illinois and currently employs 99 full-time employees. The company went IPO on 2021-02-12. The firm is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
Company Info
IPO: 2021-02-12
TALIS BIOMEDICAL CORP
1375 West Fulton Market, Suite 700
Chicago ILLINOIS 94025 US
CEO: Brian Coe
Employees: 99
Phone: 16504333000
TALIS BIOMEDICAL CORP / TLIS FAQ
Can you describe the business of TALIS BIOMEDICAL CORP?
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Chicago, Illinois and currently employs 99 full-time employees. The company went IPO on 2021-02-12. The firm is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
What is the stock price of TALIS BIOMEDICAL CORP today?
The current stock price of TLIS is 4.38 USD. The price increased by 5.29% in the last trading session.
Does TALIS BIOMEDICAL CORP pay dividends?
TLIS does not pay a dividend.
What is the ChartMill technical and fundamental rating of TLIS stock?
TLIS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is TALIS BIOMEDICAL CORP (TLIS) stock traded?
TLIS stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for TLIS stock?
TALIS BIOMEDICAL CORP (TLIS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-31.43).
What is the next earnings date for TLIS stock?
TALIS BIOMEDICAL CORP (TLIS) will report earnings on 2024-11-12, after the market close.